Results of a small French study support previous findings that Revlimid in combination with dexamethasone is effective in elderly patients with relapsed multiple myeloma.

Importantly, the researchers found that almost a third of responding patients could remain on therapy following dose adjustments, which, according to the researchers, highlights “the need for a personalized therapeutic approach according to patient age and vulnerability.” 

Revlimid (lenalidomide) in combination with dexamethasone (Decadron) is a standard therapy for patients with relapsed/refractory multiple myeloma.  Patients …

Results of a small study recently conducted at Johns Hopkins University indicate that Revlimid may boost vaccine responses in multiple myeloma patients.

Based on these results, the researchers who organized the study believe Revlimid could be used as part of a strategy to increase immune responses against both cancer and infectious diseases.

The researchers also argue that Revlimid may help reduce infections in myeloma patients being treated with the drug.  Infections are an important challenge for myeloma patients due to …

The results of a small Phase 1 clinical trial demonstrate that BT-062, a new drug specifically targeting multiple myeloma cells, shows activity and is tolerable in heavily pretreated multiple myeloma patients.

Dr. Sundar Jagannath of the Mount Sinai Medical Center in New York City presented the results at the 2011 American Society of Hematology (ASH) conference in San Diego last month.

Based on the favorable safety and activity of BT-062, a Phase 1/2 clinical trial has been initiated …

Pomalidomide was one of the potential new myeloma treatments in the spotlight at the 2011 meeting of the American Society of Hematology (ASH) held earlier this month.

The consensus is that the drug, a chemical relative of thalidomide and Revlimid, performed well during its time on the stage.

Research findings about pomalidomide (Pomalyst) were summarized in four of the meeting’s oral presentations and a number of poster presentations.

Most of these presentations examined pomalidomide’s efficacy and …

The most recent re­­sults of a Phase 2 clin­i­cal trial in­di­cate that elotuzumab in com­bi­na­tion with Revlimid and dexa­meth­a­sone is safe and ef­fec­tive in re­lapsed and re­frac­tory mul­ti­ple myeloma patients.

Dr. Sagar Lonial from the Winship Cancer In­sti­tute at the Emory Uni­ver­sity School of Medicine in Atlanta pre­sented the up­dated Phase 2 re­­sults at the American Society for He­ma­tol­ogy (ASH) annual meeting in San Diego on Monday.

The preceding Phase 1 trial of elotuzumab showed that 82 per­cent of re­lapsed / refractory …

Myeloma specialists from the Czech Republic have published clinical trial results that shed further light on chromosomal abnormalities and their impact on survival in newly diag­nosed multiple myeloma patients.

Specifically, the researchers found that patients with three or more chromos­omal abnor­malities, a gain in the 1q21 region, or the trans­location t(4;14) have reduced survival compared to patients without such abnormalities.

According to the researchers, their findings highlight the importance of chromosomal abnormalities when considering treatment options for myeloma patients.

They …

A new study by Spanish researchers sheds light on the role of stem cell transplantation in the treatment of newly diagnosed multiple myeloma.

The study focuses on newly diagnosed patients who, in a clinical trial, did not respond to initial rounds of chemotherapy to treat their disease.

It finds that, among these non-responding patients, the ones who had stable disease after their initial round of chemotherapy responded well to stem cell transplantation.

In contrast, the patients whose disease not only …